subsys
Total Payments
$1.0M
Transactions
17
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $1.0M | 17 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.0M | 17 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2 Multicenter, Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Placebo-Controlled Study of Fentanyl Sublingual Spray for the Treatment of Moderate to Severe Post-Operative Pain | INSYS Therapeutics Inc | $651,014 | 0 |
| A Phase 1, Open-Label, Crossover, Comparative Bioavailability Study of Two Formulations of Fentanyl Sublingual Spray in Healthy Volunteers | INSYS Therapeutics Inc | $223,043 | 0 |
| A Preliminary Study of Sublingual Fentanyl for the Management of Breakthrough Pain Analgesia in Patients with Advanced Cancer | INSYS Therapeutics Inc | $76,865 | 0 |
| Preliminary Study of Prophylactic Fentanyl Sublingual Spray (FSS) for Exercise-Induced Breakthrough Dyspnea | INSYS Therapeutics Inc | $57,750 | 0 |
Top Doctors Receiving Payments for subsys
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $1.0M | 17 |
Ad
Manufacturing Companies
- INSYS Therapeutics Inc $1.0M
Product Information
- Type Drug
- Total Payments $1.0M
- Total Doctors 0
- Transactions 17
About subsys
subsys is a drug associated with $1.0M in payments to 0 healthcare providers, recorded across 17 transactions in the CMS Open Payments database. The primary manufacturer is INSYS Therapeutics Inc.
Payment data is available from 2017 to 2017. In 2017, $1.0M was paid across 17 transactions to 0 doctors.
The most common payment nature for subsys is "Unspecified" ($1.0M, 100.0% of total).
subsys is associated with 4 research studies, including "A Phase 2 Multicenter, Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Placebo-Controlled Study of Fentanyl Sublingual Spray for the Treatment of Moderate to Severe Post-Operative Pain" ($651,014).